|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01099 SINOPHARM
Nominal 
15.950 -0.380 (-2.327%) | 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Turnover | 282,799,605 | -1.134% | 575,167,877 | 584,507,930 | 596,569,565 | 552,147,550 |
| Cost of Sales | (263,728,126) | -0.741% | (533,495,864) | (540,252,540) | (548,057,887) | (504,713,490) |
| Gross Profit | 19,071,479 | -6.268% | 41,672,013 | 44,255,390 | 48,511,678 | 47,434,060 |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | (1,041,018) | (1,582,079) | (2,067,764) | (1,936,170) | |
| Other Non-operating Items | 20,932 | -70.818% | (476,592) | (1,058,658) | 625,967 | 82,278 | |
| Share of Results of Asso. & JCEs | 587,105 | -14.647% | 1,232,907 | 1,199,396 | 1,107,349 | 1,067,067 | |
| Profit / (Loss) before Taxation | 6,944,889 | -3.676% | 14,799,627 | 14,000,899 | 19,512,137 | 18,563,819 | |
| Taxation | (1,765,086) | -5.744% | (3,965,193) | (3,577,305) | (4,502,309) | (4,218,377) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (1,776,030) | -5.104% | (3,679,340) | (3,373,911) | (5,956,068) | (5,819,787) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 3,403,773 | -1.786% | 7,155,094 | 7,049,683 | 9,053,760 | 8,525,655 | |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 808,716 | -18.753% | 1,994,912 | 2,328,242 | 2,430,374 | 3,189,992 |
| Depreciation & Amortisation | 1,995,892 | -10.634% | 4,289,055 | 4,733,692 | 4,430,248 | 4,165,019 |
| Directors' Emoluments | -- | -- | -- | 7,273 | 14,991 | 14,516 |
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| EPS (cts) | 109.000 | -1.802% | 229.000 | 226.000 | 290.000 | 273.000 |
| DPS (cts) | 0.000 | -- | 69.000 | 68.000 | 87.000 | 82.000 |
| Dividend Payout Ratio (%) | -- | -- | 30.131% | 30.088% | 30.000% | 30.037% |
| Cash flow per share ($) | -- | -- | 4.531 | 3.700 | 5.510 | 6.726 |
| NBV per share ($) | 27.300 | -- | 26.902 | 25.278 | 23.900 | 21.812 |
| Remarks: | Real time quote last updated: 25/08/2026 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 3,403,773 |
| %Change | -1.786% |
| EPS / (LPS) | RMB 1.090 |
| NBV Per Share (¥) | RMB 27.300 |